phospholipase A and acyltransferase 2Genealiases: HRASLS2 · PLA1/2-2 · PLAAT-2
Q-omics provides the consensus-scored PLAAT2 profile across patient tissues and cancer cell-line models. PLAAT2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, PLAAT2 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, PLAAT2 protein abundance shows 27,364 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight CESC, COAD, and LSCC as cancer lineages where PLAAT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLAAT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLAAT2 survival associations across molecular data types. PLAAT2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLAAT2 RNA expression–survival associations across cancer types. High PLAAT2 expression shows unfavorable associations in PAAD and LGG, but favorable associations in CESC, SKCM, OV and KIRC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for PLAAT2 RNA expression.
This table summarizes PLAAT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PLAAT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLAAT2 shows lower tumor expression in COAD, KICH, KIRC and KIRP and higher tumor expression in BRCA and HNSC. The COAD box plot shows higher PLAAT2 RNA expression in normal versus tumor tissue (log2 FC = −2.752, t-test p < 0.001).
This table shows molecular features associated with PLAAT2 in patient tissues and cancer cell lines. In patient samples, PLAAT2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PLAAT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
